First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J. Morgan, J. Anthony Child, Jenny Byrne et al.|The Lancet|2010Cited by 571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaBrian A. Walker, Gareth J. Morgan, Eileen M. Boyle et al.|Journal of Clinical Oncology|2015Cited by 564
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A. Walker, Gareth J. Morgan, Konstantinos Mavrommatis et al.|Blood|2018Cited by 492
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A. Walker, Gareth J. Morgan, Konstantinos Mavrommatis et al.|Leukemia|2018Cited by 452
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX StudyAndy C. Rawstron, Roger G. Owen, J. A. Child et al.|Journal of Clinical Oncology|2013Cited by 419